“People have developed hundreds of agents that can clot blood but the issue is that it’s hard to push these therapies against severe blood flow, especially far enough upstream to reach the leaking vessels. Here, for the first time, we’ve come up with an agent that can do that,” Kastrup said.
Kastrup teamed up with a group of researchers, biochemical engineers and emergency physicians to develop simple, gas-generating calcium carbonate micro-particles that can be applied in powder form to stop critical bleeding.
The particles work by releasing carbon dioxide gas, like antacid tablets, to propel them toward the source of bleeding.
The carbonate forms porous micro particles that can bind with a clotting agent known as tranexamic acid, and transport it through wounds and deep into the damaged tissue.
After studying and modeling the movement of the particles in vitro, the researchers confirmed their results using two animal models. Even in a scenario that mimicked a catastrophic event like a gunshot wound to a femoral artery, the particles proved highly effective in stopping the bleeding.
While much more rigorous testing and development is needed to bring the agent to market, the particles could have a wide range of uses, from sinus operations to treating combat wounds.
“The area we’re really focusing on is postpartum hemorrhage: in the uterus, after childbirth where you can’t see the damaged vessels but you can put the powder into that area and the particles can propel and find those damaged vessels,” said Kastrup.
VIDEO: Self-propelled powder stops severe bleeding
This study was published in today in Science Advances. The research was initially funded by the University of British Columbia and through a “Rising Stars” grant from Grand Challenges Canada. Collaborators included James Baylis, a Ph.D candidate in the Department of Biomedical Engineering at the University of British Columbia, Nathan White, a trauma specialist at the University of Washington in Seattle, Thomas Burke, the Chief of the Division of Global Health and Human Rights at Massachusetts General Hospital, Lindsay Machan from the Department of Radiology and James Piret from the Department of Chemical and Biological Engineering at the University of British Columbia.